Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,928 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
Kim DW, Lee DH, Han JY, Lee J, Cho BC, Kang JH, Lee KH, Cho EK, Kim JS, Min YJ, Cho JY, An HJ, Kim HG, Lee KH, Kim BS, Jang IJ, Yoon S, Han O, Noh YS, Hong KY, Park K. Kim DW, et al. Among authors: kim hg, kim bs, kim js. Lung Cancer. 2019 Sep;135:66-72. doi: 10.1016/j.lungcan.2019.07.007. Epub 2019 Jul 9. Lung Cancer. 2019. PMID: 31447004 Clinical Trial.
Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies.
Kim I, Yoon SS, Lee KH, Keam B, Kim TM, Kim JS, Kim HG, Oh MD, Han KS, Park MH, Park S, Kim BK. Kim I, et al. Among authors: kim hg, kim tm, kim js, kim bk. Clin Transplant. 2006 Jul-Aug;20(4):496-503. doi: 10.1111/j.1399-0012.2006.00512.x. Clin Transplant. 2006. PMID: 16842528 Clinical Trial.
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer.
Lee GW, Kang MH, Kim HG, Kang JH, Kim SH, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim HJ, Lee JS. Lee GW, et al. Among authors: kim hg, kim hj, kim sh, kim hc. Cancer Chemother Pharmacol. 2009 Jul;64(2):385-90. doi: 10.1007/s00280-008-0885-5. Epub 2008 Dec 23. Cancer Chemother Pharmacol. 2009. PMID: 19104817
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.
Hwang IG, Kang JH, Oh SY, Lee S, Kim SH, Song KH, Son C, Park MJ, Kang MH, Kim HG, Lee J, Park YS, Sun JM, Kim HJ, Kim CK, Yi SY, Jang JS, Park K, Kim HJ. Hwang IG, et al. Among authors: kim hg, kim hj, kim sh, kim ck. Support Care Cancer. 2016 Jan;24(1):301-309. doi: 10.1007/s00520-015-2783-9. Epub 2015 Jun 4. Support Care Cancer. 2016. PMID: 26041481 Clinical Trial.
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
Lim SM, Chung WY, Nam KH, Kang SW, Lim JY, Kim HG, Shin SH, Sun JM, Kim SG, Kim JH, Kang CW, Kim HR, Cho BC. Lim SM, et al. Among authors: kim hg, kim sg, kim hr, kim jh. Eur J Cancer. 2015 Aug;51(12):1588-95. doi: 10.1016/j.ejca.2015.05.020. Epub 2015 Jun 9. Eur J Cancer. 2015. PMID: 26070683 Clinical Trial.
1,928 results